94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study

Background

IO-HORIZON aimed to capture the profile, treatments and HCRU of mNSCLC pts receiving 1L IO-based treatments in routine settings.

Methods

Non-interventional, prospective study in adults with stage IIIB-IV NSCLC receiving 1L approved IO treatment. Data were collected during routine clinic visits at 6, 12 and 24 months post-1L onset.

Results

From May/2020 to Nov/2021, 240 eligible Caucasian pts (75% male, 73% urban residents, 92% with public insurance) were enrolled by 17 oncology clinics. Most pts (84%) had been diagnosed with de novo mNSCLC. Most common histology was adenocarcinoma (69%). At 1L IO initiation (median of 2.0 months after mNSCLC diagnosis), median age was 69.0 years, ECOG performance status was 0-1 in 94%, 71% had ≥1 comorbidity and NSCLC stage was mainly IV [93%; 23% of those had ≥3 metastatic sites; most common: bone (37%), contralateral lung (34%), extrathoracic lymph nodes (23%), adrenal glands (19%), brain (18%), liver (16%)]. Of tested pts (n=226), 74% had PD-L1 TPS≥1%; 31% had TPS≥50%. Treatments are shown in Table 1. In total, 84% were withdrawn before the 24-month visit mainly due to 1L IO discontinuation (62%) and death (13%). Kaplan-Meier-estimated median time on treatment was 6.6 (95% CI: 5.9-8.1) months. Over a median observation period of 6.1 months, 47% and 25% of pts had ≥1 outpatient and inpatient encounter, respectively, and 95% had ≥1 diagnostic test/procedure (Table 1). Surgery was reported in 2% and radiotherapy in 12% (most common: brain 6%; chest 4%).

Conclusions

These results provide important Real World Data on the profile and treatment patterns of 1L mNSCLC patients in Greece, showing that IO is mostly combined with chemotherapy even in cases of high PD-L1 expression and provide insights essential to support future informed healthcare policy making.

Editorial acknowledgement

Qualitis SA, a member of Optimapharm, provided medical writing and editorial support as part of the project work performed for MSD Greece.

Legal entity responsible for the study

MSD Greece.

Funding

This work was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD).

Disclosure

D. Ziogas: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, BMS, Ipsen, Pierre Fabre, Gilead, Amgen; Financial Interests, Personal, Advisory Board: Roche. H. Linardou: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, MSD, Merck, Takeda, Bristol Myers Squibb, Lilly, Pfizer, GSK, Sandoz; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, Bristol Myers Squibb, Pfizer, Amgen, Novartis; Financial Interests, Personal, Stocks/Shares: BioPath Innovations S.A.; Financial Interests, Personal and Institutional, Local PI: Bristol Myers Squibb, Boehringer Ingelheim, Roche, AbbVie, Lilly, Novartis, AstraZeneca, Amgen, PPD, Parexel ILR, Qualitis, Health Data Specialist; Financial Interests, Institutional, Local PI: GSK; Non-Financial Interests, Personal, Principal Investigator: Hellenic Cooperative Oncology Group; Non-Financial Interests, Personal, Leadership Role, Elected Chair of the Scientific Committee: Hellenic Cooperative Oncology Group; Non-Financial Interests, Personal, Member of Board of Directors: Women 4 Oncology - Hellas, Fairlife Lung Cancer Care, Hellenic Cooperative Oncology Group, Hellenic Foundation for Cancer Research. A. Charpidou: Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Pfizer, Roche. A. Koumarianou: Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: Bristol Myers Squibb, Genesis Pharma , Ipsen, Merck KGaA, MSD, Novartis, Pfizer, Roche. G. Mountzios: Financial Interests, Personal, Advisory Board: Roche, BMS, Takeda, Janssen, Sanofi; Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, Pfizer, Novartis, Amgen; Financial Interests, Institutional, Local PI: MSD; Financial Interests, Personal, Local PI: AstraZeneca, Roche, Novartis, Lilly, GSK, Amgen, Gilead Pharmaceuticals, BMS; Financial Interests, Personal, Trial Chair: AstraZeneca. C. Christodoulou: Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: AstraZeneca, Bristol Myers Squibb, AstraZeneca, Bristol Myers Squibb, Genesis Pharma, MSD, Novartis, Pfizer, Roche, Sanofi, Genesis Pharma, MSD, Novartis, Pfizer, Roche, Sanofi. D. Mavroudis: Financial Interests, Personal, Advisory Board: Pfizer. I. Korantzis: Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Merck KGaA, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi. S. Baka: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Genesis Pharma, Lilly, MSD, Novartis, Roche, Takeda. I. Athanasiadis: Financial Interests, Personal, Invited Speaker, Consultant, Advisor : AstraZeneca, Integris Pharma, MSD, Pierre Fabre ,Roche, Servier Hellas Pharmaceutique Ltd, Specifar, Novartis, Amgen, GSK, Pharmabide, Genesis Pharma, Gilead, Pharmaserve-Lilly Saci, Janssen Cilag. A. Koutras: Financial Interests, Personal, Advisory Board: Pierre Fabre, AstraZeneca, Gilead, Pfizer, Genesis, MSD, BMS, Gilead, Pfizer, Integris, BMS, AstraZeneca; Financial Interests, Personal, Invited Speaker: Sanofi, Gilead, AstraZeneca, Sandoz, Gilead; Financial Interests, Personal, Other, Travel, Accommodations: Rafarm, Lilly, Ipsen, Gilead, Pfizer; Financial Interests, Personal, Other, Travel, Accommodations: Genesis, AstraZeneca; Financial Interests, Personal, Other, Conference registration (Web): Ipsen; Financial Interests, Institutional, Funding: Lilly, Pfizer, Merck, AstraZeneca, Gilead; Financial Interests, Institutional, Research Grant: AstraZeneca, Pierre Fabre, BMS, DEMO, Faran, Amgen, Roche, Ipsen, Galenica, Win Medica; Financial Interests, Personal, Funding: Merck. D. Mauri: Financial Interests, Personal, Speaker, Consultant, Advisor: MSD. F. Spanoudi: Financial Interests, Institutional, Full or part-time Employment, Filio Spanoudi is full time employee of MSD Greece: MSD Greece. T. Tsichritzis: Other, Institutional, Full or part-time Employment, Theodoros Tsichritzis is full time employee of MSD Greece: MSD Greece. K. Syrigos: Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Novartis, Pfizer, Roche, Takeda. All other authors have declared no conflicts of interest.